Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEM 3454 for Cognitive Impairment in Schizophrenia
NCT00604760Phase 2Unknown
- Sponsor
- Memory Pharmaceuticals
- Start
- Dec 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of facinicline in schizophrenia (4 arms), sponsored by Memory Pharmaceuticals. Primary endpoint: Total composite score of the MATRICS cognitive battery at 8 weeks. Status: unknown.
02
Drugs
facinicline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00604760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00604760.